SERIOUS ADVERSE EVENT FORM AGO

|  |
| --- |
|  |
| **EVENT N°: *(site\chronologic number of event; e.g. UZ Gent\001)*** ................... **\** .................. |

|  |  |
| --- | --- |
| **Report Type:** | ❑ Initial Report❑ Follow-up Report n°………………… |

|  |  |  |
| --- | --- | --- |
| **STUDY DRUG INFORMATION:** |  | **SUBJECT INFORMATION:** |
| Name drug (INN, trade name if possible): |  |  | Subject number: |  |
| Daily dose: |  |  | Year of birth: |  |
| Route of administration: |  |  |  |  |
| Therapy days (from/to, time of day): |  |  |  |  |

|  |  |
| --- | --- |
| **DESCRIPTION OF SAE:** |  |
| Previously reported as :(if applicable)  |  |
| Criterion for considering the AE as serious.Any untoward medical occurrence that at any dose: | ❑ Results in death❑ Is life-threatening❑ Requires inpatient hospitalization or prolongation of existing hospitalization❑ Results in persistent or significant disability or incapacity❑ Is a congenital anomaly or birth defect❑ Is considered as an important medical event |
| Date (yyyy-mm-dd) and time of onset of the reaction: |  |
| Date of study personnel’s awareness of the event (yyyy-mm-dd) |  |
| Severity or CTCAE-Grade | **CTCAE-Grade:** ❑ Grade 1 ❑Grade 2 ❑Grade 3 ❑Grade 4 ❑Grade 5**Or****Intensity:** ❑ mild ❑ moderate ❑ severe |
| Actions taken:*(please provide all actions taken, i.e. diagnostic procedures, treatment, referral to other departments,…)* |  |
| Outcome of the event: | ❑ Resolved, date (yyyy-mm-dd): ………...............................................................❑ Resolved with sequelae, date (yyyy-mm-dd): ………........................................❑ Ongoing❑ Death, date of death (yyyy-mm-dd): ………......................................................❑ Unknown, explain ……………………………………………………………... |
| Changed Outcome of the event in case of Follow-up Report: | ❑ Resolved, date (yyyy-mm-dd): ………..............................................................❑ Resolved with sequelae, date (yyyy-mm-dd): ……….......................................❑ Ongoing❑ Death, date of death (yyyy-mm-dd): ………......................................................❑ Unknown, explain ……………………………………………………………... |
| De-challenge and/or re-challenge information: |  |
| Setting (hospital, home, …): |  |

|  |
| --- |
| **SAE NARRATIVE:** Give a detailed description of the serious adverse event, including full description of the signs or symptoms, event duration, treatment administered, actions taken and outcome. Also describe any relevant history. |
|  |

|  |
| --- |
| **CONCOMITANT MEDICATIONS:****(Including additional (non-)investigational study drugs)** |
| **Drug Name****(Trade name, if possible)** | **Dose, route of administration, regimen** | **Start & stop dates****(yyyy-mm-dd)** | **Reason for administration** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |
| --- |
| **RELEVANT LABORATORY AND DIAGNOSTIC TESTS OR PROCEDURES:** |
| **Date(yyyy-mm-dd)** | **Test** | **Results (+ normal range if applicable)****Please attach report when possible** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

|  |
| --- |
| **ASSESSMENT OF CAUSALITY BY (PRINCIPAL) INVESTIGATOR:** |
| Is SAE related to trial medication? | ❑ Not related❑ Unlikely❑ Possibly❑ Probably❑ Definitely |
| **REMARKS:** |
|  |
| **SIGNATURES:** |
| Report completed by:Print Name: Signature:  | ............................................................................................................................................................ Date (yyyy-mm-dd): ............................ |
| I have reviewed this serious adverse event report and find it to be complete and accurate.Signature of Investigator: .............................................................................. Date (yyyy-mm-dd): ............................ |

*Only for completion by Coordinating Investigator U(Z) Gent*

|  |
| --- |
| **ASSESSMENT COORDINATING INVESTIGATOR (or delegate):** |
| Is SAE related to the trial medication (i.e. investigational medicinal product, comparator or placebo)?*(see study protocol for definition)* | ❑ Not related❑ Unlikely❑ Possibly❑ Probably❑ Definitely |
| Is the SAE unexpected?(e.g. not listed in IB, SmPC) | ❑ Yes, unexpected❑ NoExplain and mention source: ............................................................... |
| Is this a SUSAR?(A SUSAR is a SAE which is at least possibly related **and** unexpected) | ❑ Yes❑ No | Note: For SUSARs, send form **immediately** to HIRUZ CTU for reporting to EMA through the Eudravigilance database. |

|  |
| --- |
| **SIGNATURE COORDINATING INVESTIGATOR:** |
| I agree with the assessment of this serious adverse event report. |
| Print Name Coordinating Investigator or delegate: Signature Coordinating Investigator (or delegate):Date (yyyy-mm-dd) | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ / \_\_\_\_\_\_ / \_\_\_\_\_\_ |